Standout Papers

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inad... 2004 2026 2011 2018 815
  1. Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE (2004)
    Marc Humbert, Richard Beasley et al. Allergy

Immediate Impact

2 from Science/Nature 77 standout
Sub-graph 1 of 20

Citing Papers

Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
2024 Standout
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
2024 Standout
2 intermediate papers

Works of K.M. Beeh being referenced

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
2004 Standout

Author Peers

Author Last Decade Papers Cites
K.M. Beeh 644 822 420 10 868
T.F. Reiss 761 909 317 10 1000
K. Surrey 797 1080 637 9 1.1k
Philippe Godard 683 724 146 12 889
Carlos Fernández Vidaurre 444 601 351 7 850
A M Vignola 538 630 255 13 784
Gun Almqvist 419 721 247 16 879
L Schwartz 260 513 202 11 892
Leen Gilles 401 421 124 15 1000
Yanping Wu 609 899 246 14 970
Sabine Kony 350 409 254 14 881

All Works

Loading papers...

Rankless by CCL
2026